Positron Emission Tomography with [18F]ROStrace Reveals Progressive Elevations in Oxidative Stress in a Mouse Model of Alpha-Synucleinopathy
暂无分享,去创建一个
Hsiaoju S Lee | Shihong Li | Kuiying Xu | Malkah Sheldon | Kelvin C. Luk | Catherine Hou | Evan Gallagher | Yi Zhu | Chia-Ju Hsieh | Patrick Henderson | Rea Chroneos | Shaipreeah Riley | Kelvin C. Luk | Robert H Mach | Meagan Mcmanus
[1] C. Lee,et al. Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson's disease. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] D. D. Di Monte,et al. Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading , 2022, Science advances.
[3] Ji Youn Lee,et al. [18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer’s disease pathology in APP/PS1 mice , 2022, bioRxiv.
[4] T. Weissman,et al. Phosphorylation of the aggregate-forming protein alpha-synuclein on serine-129 inhibits its DNA-bending properties , 2021, The Journal of biological chemistry.
[5] C. Dobson,et al. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells , 2021, Nature Communications.
[6] Pablo Aguiar,et al. Intensity normalization methods in brain FDG-PET quantification , 2020, NeuroImage.
[7] Meir Schechter,et al. α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate , 2020, The Journal of Biological Chemistry.
[8] S. Duchesne,et al. Selection of the optimal intensity normalization region for FDG-PET studies of normal aging and Alzheimer’s disease , 2020, Scientific Reports.
[9] Fei Zou,et al. Poly (ADP‐ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α‐synuclein degradation via transcription factor EB‐dependent autophagy in mutant α‐synucleinA53T model of Parkinson's disease , 2020, Aging cell.
[10] E. Masliah,et al. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment. , 2019, Free radical biology & medicine.
[11] Nikhil Panicker,et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.
[12] D. D. Di Monte,et al. Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. , 2019, The Journal of clinical investigation.
[13] T. Weissman,et al. Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders , 2019, Scientific Reports.
[14] Shu-Ying Liu,et al. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease. , 2018, Food & function.
[15] J. Troncoso,et al. Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease , 2018, Science.
[16] K. Schroder,et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice , 2018, Science Translational Medicine.
[17] N. Forsyth,et al. Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors , 2018, Front. Cell Dev. Biol..
[18] T. Südhof,et al. Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.
[19] O. El‐Agnaf,et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice , 2017, Scientific Reports.
[20] M. Mintun,et al. Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation , 2017, ACS chemical neuroscience.
[21] J. Rinne,et al. Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal 18F-FDG and 18F-DPA-714 PET imaging , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] V. Lee,et al. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production , 2017, Cellular and Molecular Life Sciences.
[23] J. Pu,et al. Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease , 2017, Journal of movement disorders.
[24] T. Myöhänen,et al. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector–Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain , 2016, The Journal of Neuroscience.
[25] N. Albert,et al. Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study , 2016, The Journal of Nuclear Medicine.
[26] W. Poewe,et al. The Concept of Prodromal Parkinson’s Disease , 2015, Journal of Parkinson's disease.
[27] Syed F. Ali,et al. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models. , 2015, Brain : a journal of neurology.
[28] Vivek K Unni,et al. Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism , 2015, Cell reports.
[29] B. Harvey,et al. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse , 2014, Neurobiology of Disease.
[30] S. Chandra,et al. Synucleins Regulate the Kinetics of Synaptic Vesicle Endocytosis , 2014, The Journal of Neuroscience.
[31] M. Mintun,et al. Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in vivo. , 2014, Organic & biomolecular chemistry.
[32] N. Chandel,et al. ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.
[33] Z. Berger,et al. Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson’s Disease , 2013, PloS one.
[34] Jiajie Diao,et al. Properties of native brain α-synuclein , 2013, Nature.
[35] R. Parsey,et al. Reference Region Approaches in PET: a Comparative Study on Multiple Radioligands , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[36] Axel T Brunger,et al. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2 , 2013, eLife.
[37] Rafael Radi,et al. Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects. , 2013, Accounts of chemical research.
[38] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[39] E. Masliah,et al. Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. , 2012, Human molecular genetics.
[40] A. Negro,et al. α-Synuclein Controls Mitochondrial Calcium Homeostasis by Enhancing Endoplasmic Reticulum-Mitochondria Interactions* , 2012, The Journal of Biological Chemistry.
[41] Bernard Schneider,et al. α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.
[42] J. Franklin,et al. The Mitochondria-Targeted Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[43] Jau-Shyong Hong,et al. Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease , 2011, Environmental health perspectives.
[44] J. Andersen,et al. Synergistic effects of environmental risk factors and gene mutations in Parkinson’s disease accelerate age‐related neurodegeneration , 2010, Journal of neurochemistry.
[45] S. Kalivendi,et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. , 2010, Free radical biology & medicine.
[46] T. Südhof,et al. α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.
[47] A. Sidhu,et al. Mice expressing the A53T mutant form of human alpha‐synuclein exhibit hyperactivity and reduced anxiety‐like behavior , 2010, Journal of neuroscience research.
[48] Xiaohui Xu,et al. Nitrated α-Synuclein Induces the Loss of Dopaminergic Neurons in the Substantia Nigra of Rats , 2010, PloS one.
[49] Ad Bax,et al. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. , 2009, Journal of molecular biology.
[50] L. Forno,et al. Pathologic Modifications of &agr;-Synuclein in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Treated Squirrel Monkeys , 2008, Journal of neuropathology and experimental neurology.
[51] N. Avadhani,et al. Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.
[52] H. Kato,et al. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease , 2008, Metabolic Brain Disease.
[53] M. Parihar,et al. Mitochondrial association of alpha-synuclein causes oxidative stress , 2008, Cellular and Molecular Life Sciences.
[54] H. Gendelman,et al. Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.
[55] Joanna S. Fowler,et al. A novel approach for imaging brain–behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator , 2007, NeuroImage.
[56] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[57] H. Gendelman,et al. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease , 2007, Journal of neurochemistry.
[58] Leonidas Stefanis,et al. α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis , 2006, The Journal of Neuroscience.
[59] R. Deacon. Assessing nest building in mice , 2006, Nature Protocols.
[60] Hongtao Zhao,et al. Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[61] Belinda Wilson,et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] Ad Bax,et al. Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.
[63] Rafael Radi,et al. Nitric oxide, oxidants, and protein tyrosine nitration , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[64] S. Przedborski,et al. Nitric Oxide and Reactive Oxygen Species in Parkinson's Disease , 2003, IUBMB life.
[65] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[66] J. Trojanowski,et al. Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.
[67] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[68] J. Trojanowski,et al. Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.
[69] Virginia M. Y. Lee,et al. Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.
[70] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[71] J. Trojanowski,et al. Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.
[72] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[73] H. Ischiropoulos. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.
[74] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[75] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[76] J S Beckman,et al. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.
[77] Guy B. Williams,et al. SPMMouse: A new toolbox for SPM in the animal brain , 2009 .
[78] Jun Guo,et al. Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells , 2007, Cellular and Molecular Neurobiology.